Literature DB >> 7045358

Standard methodology for Segment I, II, and III Pediatric Rheumatology Collaborative Study Group studies. I. Design.

E J Brewer, E H Giannini.   

Abstract

Mesh：

Substances：

Year:  1982        PMID： 7045358

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  13 in total

Review 1.  Outcome measures and medical progress: why outcome measures are needed in childhood arthritis.

Authors:  Francesco Zulian
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

Review 2.  Network in pediatric rheumatology: the example of the Pediatric Rheumatology International Trials Organization.

Authors:  Nicolino Ruperto; Alberto Martini
Journal:  World J Pediatr       Date:  2008-08       Impact factor: 2.764

Review 3.  Advances from clinical trials in juvenile idiopathic arthritis.

Authors:  Daniel J Lovell; Nicola Ruperto; Edward H Giannini; Alberto Martini
Journal:  Nat Rev Rheumatol       Date:  2013-07-09       Impact factor: 20.543

4.  Quantitative MR characterization of disease activity in the knee in children with juvenile idiopathic arthritis: a longitudinal pilot study.

Authors:  Dagnachew W Workie; T Brent Graham; Tal Laor; Akila Rajagopal; Kendall J O'Brien; Wendy A Bommer; Judy M Racadio; Norah J Shire; Bernard J Dardzinski
Journal:  Pediatr Radiol       Date:  2007-03-31

5.  Blood gold concentrations in children with juvenile rheumatoid arthritis undergoing long-term oral gold therapy.

Authors:  E H Giannini; E J Brewer; D A Person
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

6.  Poor correlation between the erythrocyte sedimentation rate and clinical activity in juvenile rheumatoid arthritis.

Authors:  E H Giannini; E J Brewer
Journal:  Clin Rheumatol       Date:  1987-06       Impact factor: 2.980

7.  Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment.

Authors:  Marion A J van Rossum; Renée M van Soesbergen; Maarten Boers; Aeilko H Zwinderman; Theo J W Fiselier; Marcel J A M Franssen; Rebecca ten Cate; Lisette W A van Suijlekom-Smit; Nico M Wulffraat; Wilma H J van Luijk; Johanna C M Oostveen; Wietse Kuis; Ben A C Dijkmans
Journal:  Ann Rheum Dis       Date:  2007-05-09       Impact factor: 19.103

8.  Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials.

Authors:  N Ruperto; E H Giannini
Journal:  Ann Rheum Dis       Date:  1996-01       Impact factor: 19.103

9.  Bone turnover is reduced in children with juvenile rheumatoid arthritis.

Authors:  F Falcini; M Ermini; F Bagnoli
Journal:  J Endocrinol Invest       Date:  1998-01       Impact factor: 4.256

Review 10.  Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan.

Authors:  Masaaki Mori; Takuya Naruto; Tomoyuki Imagawa; Takuji Murata; Syuji Takei; Minako Tomiita; Yasuhiko Itoh; Satoshi Fujikawa; Shumpei Yokota
Journal:  Mod Rheumatol       Date:  2008-09-25       Impact factor: 3.023
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.